Skip to search formSkip to main contentSkip to account menu

NSC 290205

Known as: NSC-290205 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AzasteroidsNitrogen Mustard Compounds
NSC-71964

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
NSC 290205-based therapy in murine pancreatic adenocarcinoma PAN02 in combination with adriamycin (ADR).
BACKGROUND NSC 290205 (A) is a hybrid synthetic antitumor ester, which combines a D-lactam derivative of androsterone and… 
Review
2006
Review
2006
A preclinical survey on the efficacy of NSC-290205 in combination with doxorubicin (ADR) in Lewis lung carcinoma (LLC).
17131 Background: NSC-290205 (A) is a hybrid synthetic antitumor ester, which combines a D-lactam derivative of androsterone and… 
1984
1984
Further studies on the anti-neoplastic activity of 3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam [p-[bis(2-chloroethyl)amino]-phenyl]acetate (NSC 290205).
The modified steroidal alkylating agent 3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam [p-[bis(2… 
1982
1982
Activity of 3β-Hydroxy-13α-Amino-13,17-Seco-5α-Androstane-17-oic-13,17-Lactam(p-(bis(2-Chloroethyl)amino)-Phenyl)acetate (NSC 290205) in Murine Solid Tumors
The modified steroidal alkylating agent, 3 β -hydroxy-13α-amino-13,17-seco-5α-androstane-17-oic-13,17-lactam[p-[bis(2-chloroethyl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)